What Is Sapropterin and How Does It Work?
Sapropterin (Kuvan) is a synthetic form of tetrahydrobiopterin (BH4), a cofactor for phenylalanine hydroxylase (PAH). In phenylketonuria (PKU), it boosts residual PAH activity to lower blood phenylalanine (Phe) levels in responsive patients.[1]
Role of Baseline BH4 Levels in Response
Patients with higher baseline endogenous BH4 levels show better Phe reduction with sapropterin. Low BH4 (<30 nmol/L in cerebrospinal fluid or plasma) correlates with poor response, as the drug supplements deficient cofactor. High-BH4 patients (>30 nmol/L) often achieve >30% Phe drop, enabling dietary Phe relaxation.[2][3]
Testing BH4 Levels for Predictability
BH4 loading tests measure Phe drop after BH4 challenge, predicting sapropterin response (positive if >30% reduction). Direct BH4 assays (e.g., via CSF or dried blood spots) refine this: BH4-deficient PKU variants respond less, while BH4-sufficient ones do better. Genotyping PAH mutations also flags BH4-responsive types.[4]
Why Do Low BH4 Levels Reduce Response?
Insufficient BH4 limits PAH saturation even with sapropterin. High endogenous BH4 allows full cofactor loading, enhancing Phe metabolism. Studies show BH4/BH2 ratios matter—oxidized BH2 competes, so low functional BH4 predicts non-response.[5]
Clinical Cutoffs and Patient Outcomes
- Responsive: Baseline BH4 >15-20 pmol/10^6 cells, >30% Phe drop at 24 hours.
- Non-responsive: BH4 <10 pmol/10^6 cells, <20% drop.
Long-term, responsive patients maintain Phe <360 μmol/L on lower doses (10-20 mg/kg/day).[6]
Factors Influencing BH4 Impact
Dietary folate, genetics (e.g., DHPR deficiency), and age affect BH4 recycling. Kids under 6 respond best; adults with low BH4 may need higher doses or alternatives like pegvaliase.[7]
Alternatives for Low-BH4 Non-Responders
Low-BH4 patients rely on Phe-restricted diets or enzyme substitutes. No direct BH4 enhancers approved, but folinic acid trials aim to boost recycling.[8]
[1]: FDA Label for Kuvan
[2]: Muntau et al., Mol Genet Metab 2011
[3]: Blau et al., J Inherit Metab Dis 2010
[4]: Vockley et al., Mol Genet Metab 2014
[5]: Feldman et al., J Pediatr 2013
[6]: Burton et al., Pediatrics 2007
[7]: van Spronsen et al., Orphanet J Rare Dis 2017
[8]: Hill et al., Ann Clin Biochem 2020